FOXO4-DRI is a D-retro-inverso peptide that disrupts the FOXO4-p53 interaction, and people run it as a senolytic to clear senescent cells, with a smaller set using it for anti-aging and longevity broadly. The most common community dose is 10 milligrams daily, and clinician protocols land in the 5–10 milligram range, dosed subcutaneously in short cycles of two to six weeks. There is no FDA-approved indication; all human use is off-label or compounded, and the supporting evidence remains animal-only. Report volume is still low, so both the efficacy and safety picture should be read as preliminary.
Data last updated
Measured on 4 of 6 axes
Evidence shape
FOXO4-DRI currently exists strictly within the realm of animal-only research, with no published human trials or clinical data available. The existing evidence is limited to preclinical and mechanistic studies, providing no basis for human efficacy or safety profiles. Because there are zero registered trials and no completed human studies, the peptide lacks the necessary data to support any therapeutic application. This absence of human-grade evidence means that all current understanding of the peptide remains confined to laboratory models.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 14 out-of-stock offers not shown
How FOXO4-DRI is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
Clinician practice reports subcutaneous dosing of FOXO4‑DRi at 5 mg to 10 mg taken once daily, with some users opting for the lower 5 mg dose and others the full 10 mg.
Most community reports did not specify a schedule, typically using 3 mg (range 10 µg–25 mg); a minority reported daily or every‑other‑day dosing (2 reports each) and occasional twice‑daily, thrice‑weekly, every few days, or weekly patterns.